RiverVest

OncoResponse Inc. is an immuno-oncology company based in Houston, Texas, focused on discovering new cancer immunotherapies and therapeutic antibodies. The company collaborates with MD Anderson Cancer Center to utilize the I-STAR™ platform, which analyzes the human memory B-cell repertoire of patients who have demonstrated exceptional responses to immunotherapy, referred to as "Elite Responders." By studying these patients, OncoResponse aims to harness the human immune system to identify fully human monoclonal antibodies and novel targets. This approach is intended to facilitate the development of innovative antibody-derived therapeutics for cancer treatment.

Good Therapeutics develops new technology for self-regulating drugs that will provide a therapeutic activity when, where it is needed. It is an early-stage biotechnology company based in Seattle, Washington. They are developing context-dependent protein drugs that sense biomarkers and respond with therapeutic activity. Their goal is to make safer, more effective drugs that act only when and where they are needed, limiting systemic toxicity without reducing therapeutic efficacy. Their core technology is an algorithm for designing allosterically-regulated proteins. These proteins change their conformation (shape) when they bind a biomarker or metabolite, and in doing so activate a therapeutic domain. They are currently focused on immuno-oncology applications of the technology.

VentureMed Group (VMG) designs, develops and markets innovative medical devices which enable interventionalists to cost effectively treat peripheral artery diseases and improve the lives of their patients. Founded by physicians who understand the clinical, medical and financial demands in today’s healthcare environment, VMG creates truly cost effective solutions. Their flagship product, the FLEX Scoring Catheter enables providers to reduce expensive inventory costs while offering the interventionalist more treatment options from a single device.

Biolinq Inc. is a San Diego-based company that specializes in developing skin-applied electronic sensors designed to analyze body fluids for health monitoring. Founded in 2012 and originally known as Electrozyme LLC, Biolinq aims to enhance the experience of individuals with diabetes by providing a more affordable and pain-free alternative to conventional continuous glucose monitoring (CGM) systems. The company's platform features minimally invasive electrochemical biosensors capable of measuring multiple analytes, including glucose, ketones, and lactate. This innovative technology not only facilitates easier blood glucose monitoring but also delivers actionable insights into metabolic health, significantly improving the quality of life for patients managing diabetes.

Scout Bio, Inc. researches and develops one-time therapies for major chronic pet health conditions using veterinary biotechnology and gene therapy. It offers therapies for anemia associated with chronic kidney disease (CKD) in cats. The company offers pet therapeutics, including small molecular drugs, protein therapies, and gene therapies. Scout Bio, Inc. was founded in 2016 and is headquartered in Philadelphia, Pennsylvania.

Wugen is a biotechnology company focused on developing innovative CAR-T therapies for T-cell malignancies. Utilizing advanced gene editing technologies, Wugen aims to address the challenges associated with the clinical development of allogeneic CAR-T cells. The company is working on next-generation off-the-shelf memory natural killer (NK) and CAR-T cell therapies, leveraging its proprietary Moneta platform and deep expertise in genomic engineering. These efforts are directed toward creating a new class of memory NK cell therapies to effectively treat both hematological and solid tumor malignancies, ultimately enhancing the medical community's ability to combat life-threatening cancers.

Glycomine, Inc. is a biotechnology company based in San Carlos, California, established in 2014. The company specializes in developing nanomedicines aimed at treating rare genetic disorders, particularly those related to protein and lipid glycosylation. These disorders often lead to significant health challenges for affected individuals, and Glycomine focuses on creating therapeutics for diseases that currently lack FDA-approved treatment options. With approximately 7,000 rare disorders identified worldwide, and a majority of them without viable therapies, Glycomine is positioned to address critical unmet medical needs in this niche area of healthcare.

Standard Bariatrics is a medical device company based in Cincinnati, Ohio, founded in 2014. The company specializes in the development of surgical instruments designed for weight loss surgeries, particularly laparoscopic sleeve gastrectomy. One of its key products is the Standard Clamp, which assists surgeons in standardizing their techniques to minimize variation, enhance efficiency, and reduce waste during procedures. Additionally, the company's disposable surgical tools complement general-use endoscopic staplers, allowing surgeons to decrease the number of cartridges used in surgeries and ultimately lowering costs. Through these innovations, Standard Bariatrics aims to improve surgical outcomes and streamline the weight loss surgery process.

Sparrow Pharmaceuticals, founded in 2013 and based in Portland, Oregon, focuses on developing targeted therapies for conditions related to corticosteroid excess. The company aims to provide innovative treatment options for disorders linked to elevated levels of cortisol, which can arise from tumors or prolonged use of corticosteroid medications like prednisone. By addressing serious issues associated with hypercortisolism, Sparrow Pharmaceuticals seeks to enhance the management of autoimmune and inflammatory conditions, ultimately improving patient care and outcomes in this challenging medical area.

Tioma Therapeutics, Inc. operates as an immuno-oncology company that develops anti-CD47 antibodies for the treatment of solid and hematologic cancers. Tioma Therapeutics, Inc. was formerly known as Vasculox, Inc. and changed its name to Tioma Therapeutics, Inc. in August 2016. The company was founded in 2006 and is based in St. Louis, Missouri with a corporate office in Brisbane, California.

SeQure DX is in the business activities at non-commercial site business. It was founded in 2020 and is based in Waltham, Massachusetts.

OncoResponse Inc. is an immuno-oncology company based in Houston, Texas, focused on discovering new cancer immunotherapies and therapeutic antibodies. The company collaborates with MD Anderson Cancer Center to utilize the I-STAR™ platform, which analyzes the human memory B-cell repertoire of patients who have demonstrated exceptional responses to immunotherapy, referred to as "Elite Responders." By studying these patients, OncoResponse aims to harness the human immune system to identify fully human monoclonal antibodies and novel targets. This approach is intended to facilitate the development of innovative antibody-derived therapeutics for cancer treatment.

Xilio Therapeutics is a biotechnology company advancing next-generation cancer immunotherapies designed to improve patient outcomes by unleashing the power of the immune system selectively at the site of the tumor. The company’s tumor-selective immunotherapies are based on its proprietary technology, which maximizes the potency of proven immuno-oncology therapies and restricts their activity to the tumor to minimize peripheral side effects. The broad applicability of these therapies across cancer types means that all patients could benefit from these potentially curative medicines. These tumor-selective therapies are designed to overcome the significant toxicities associated with validated IO therapies, such as IL-2 and aCTLA4, which have historically limited the number of patients that can be treated and prevented patients from completing full courses of treatment Xilio Therapeutics proprietary technology enables the explosion of therapeutic activity specifically within the tumor while reducing toxicity throughout the body a nod to the company name, Xilio, derived from the Latin term, Ex Nihilo, meaning creation or big-bang. The company applying its technology to build a broad pipeline of engineered antibodies, cytokines and chemokines as potential new options for people living with cancer. Xilio Therapeutics was founded in 2016 and is headquartered in Waltham, Massachusetts, United States.

Reneo Pharmaceuticals is an operator of a pharmaceutical company used to develop therapies for patients with orphan metabolic diseases. It focuses on the development of treatments for genetic disorders associated with defects in energy metabolism resulting in myopathy that enable caregivers to improve the daily function and quality of life of patients suffering from these diseases by improving how their mitochondria work, preserving muscle function and preventing muscle injury, weakness, and wasting. The company was founded in 2014 and is headquartered in San Diego, California.

Amplyx Pharmaceuticals is a pre-clinical stage company focusing on the development of small molecule drugs with enhanced efficacy and lower toxicity. Amplyx employs a platform approach to improve small molecule drugs by the addition of a second small molecule to an existing drug. The company develops innovative therapies for debilitating and life-threatening diseases that affect people with compromised immune systems. Amplyx Pharmaceuticals was founded in 2006 and is headquartered in San Diego, California.

Good Therapeutics develops new technology for self-regulating drugs that will provide a therapeutic activity when, where it is needed. It is an early-stage biotechnology company based in Seattle, Washington. They are developing context-dependent protein drugs that sense biomarkers and respond with therapeutic activity. Their goal is to make safer, more effective drugs that act only when and where they are needed, limiting systemic toxicity without reducing therapeutic efficacy. Their core technology is an algorithm for designing allosterically-regulated proteins. These proteins change their conformation (shape) when they bind a biomarker or metabolite, and in doing so activate a therapeutic domain. They are currently focused on immuno-oncology applications of the technology.

Avalyn Pharma is a biopharma company that advances therapies for the treatment of Idiopathic Pulmonary Fibrosis (IPF) and other severe respiratory diseases. Its therapies rapidly advance AP01 for the treatment of IPF, provides additional pipeline candidates for IPF, improve the care and outcomes of severe respiratory diseases, and develop novel inhaled therapeutics. Avalyn Pharma was established in 2011 and is headquartered in Seattle, Washington.

Xilio Therapeutics is a biotechnology company advancing next-generation cancer immunotherapies designed to improve patient outcomes by unleashing the power of the immune system selectively at the site of the tumor. The company’s tumor-selective immunotherapies are based on its proprietary technology, which maximizes the potency of proven immuno-oncology therapies and restricts their activity to the tumor to minimize peripheral side effects. The broad applicability of these therapies across cancer types means that all patients could benefit from these potentially curative medicines. These tumor-selective therapies are designed to overcome the significant toxicities associated with validated IO therapies, such as IL-2 and aCTLA4, which have historically limited the number of patients that can be treated and prevented patients from completing full courses of treatment Xilio Therapeutics proprietary technology enables the explosion of therapeutic activity specifically within the tumor while reducing toxicity throughout the body a nod to the company name, Xilio, derived from the Latin term, Ex Nihilo, meaning creation or big-bang. The company applying its technology to build a broad pipeline of engineered antibodies, cytokines and chemokines as potential new options for people living with cancer. Xilio Therapeutics was founded in 2016 and is headquartered in Waltham, Massachusetts, United States.

Spruce Biosciences is a clinical-stage biopharmaceutical focused on developing new treatments for rare endocrine disorders. The company is driven by its mission is to develop meaningful therapies for patients with rare diseases affecting the hypothalamic-pituitary-adrenal. They are committed to transforming the quality of life for patients who have been underserved by scientific innovation.

InterVene, Inc. is a medical device company based in South San Francisco, California, focused on developing innovative catheter-based therapies for chronic venous insufficiency (CVI) caused by deep vein valve failure. Founded in 2011, InterVene aims to transform the treatment of severe venous disease in the legs by introducing a novel, non-implantable catheter approach that enables physicians to create new vein valves. This technology addresses a significant unmet need for patients suffering from painful venous stasis ulcers and other debilitating symptoms associated with deep vein reflux. By providing an effective therapy for CVI, InterVene seeks to improve the quality of life for millions of Americans affected by this condition.

Reneo Pharmaceuticals is an operator of a pharmaceutical company used to develop therapies for patients with orphan metabolic diseases. It focuses on the development of treatments for genetic disorders associated with defects in energy metabolism resulting in myopathy that enable caregivers to improve the daily function and quality of life of patients suffering from these diseases by improving how their mitochondria work, preserving muscle function and preventing muscle injury, weakness, and wasting. The company was founded in 2014 and is headquartered in San Diego, California.

Scout Bio, Inc. researches and develops one-time therapies for major chronic pet health conditions using veterinary biotechnology and gene therapy. It offers therapies for anemia associated with chronic kidney disease (CKD) in cats. The company offers pet therapeutics, including small molecular drugs, protein therapies, and gene therapies. Scout Bio, Inc. was founded in 2016 and is headquartered in Philadelphia, Pennsylvania.

Tioma Therapeutics, Inc. operates as an immuno-oncology company that develops anti-CD47 antibodies for the treatment of solid and hematologic cancers. Tioma Therapeutics, Inc. was formerly known as Vasculox, Inc. and changed its name to Tioma Therapeutics, Inc. in August 2016. The company was founded in 2006 and is based in St. Louis, Missouri with a corporate office in Brisbane, California.

Good Therapeutics develops new technology for self-regulating drugs that will provide a therapeutic activity when, where it is needed. It is an early-stage biotechnology company based in Seattle, Washington. They are developing context-dependent protein drugs that sense biomarkers and respond with therapeutic activity. Their goal is to make safer, more effective drugs that act only when and where they are needed, limiting systemic toxicity without reducing therapeutic efficacy. Their core technology is an algorithm for designing allosterically-regulated proteins. These proteins change their conformation (shape) when they bind a biomarker or metabolite, and in doing so activate a therapeutic domain. They are currently focused on immuno-oncology applications of the technology.

Mirum Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of therapies for debilitating liver diseases. It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.

Cardialen, Inc., a medical device company that develops a therapy system that detects and treats atrial fibrillation, rapid ventricular tachycardia, and ventricular fibrillation. It offers an implantable device to restore normal heart rhythm and may reduce the potential for high-energy defibrillation shocks. The company was incorporated in 2008 and is based in Minneapolis, Minnesota.

OncoResponse Inc. is an immuno-oncology company based in Houston, Texas, focused on discovering new cancer immunotherapies and therapeutic antibodies. The company collaborates with MD Anderson Cancer Center to utilize the I-STAR™ platform, which analyzes the human memory B-cell repertoire of patients who have demonstrated exceptional responses to immunotherapy, referred to as "Elite Responders." By studying these patients, OncoResponse aims to harness the human immune system to identify fully human monoclonal antibodies and novel targets. This approach is intended to facilitate the development of innovative antibody-derived therapeutics for cancer treatment.

Standard Bariatrics is a medical device company based in Cincinnati, Ohio, founded in 2014. The company specializes in the development of surgical instruments designed for weight loss surgeries, particularly laparoscopic sleeve gastrectomy. One of its key products is the Standard Clamp, which assists surgeons in standardizing their techniques to minimize variation, enhance efficiency, and reduce waste during procedures. Additionally, the company's disposable surgical tools complement general-use endoscopic staplers, allowing surgeons to decrease the number of cartridges used in surgeries and ultimately lowering costs. Through these innovations, Standard Bariatrics aims to improve surgical outcomes and streamline the weight loss surgery process.

Allakos Inc. is a clinical-stage biopharmaceutical company based in Redwood City, California, founded in 2012. The company specializes in developing antibody-based therapeutics aimed at treating various diseases linked to dysregulation of the T-helper type 2 immune response, including allergic diseases, inflammation, and conditions characterized by excessive inflammatory cell production. Its lead therapeutic candidate, antolimab (AK002), targets conditions such as eosinophilic gastritis, eosinophilic gastroenteritis, chronic urticaria, indolent systemic mastocytosis, and severe allergic conjunctivitis. Additionally, Allakos is advancing another program, AK006, which targets the Siglec-6 receptor on mast cells to modulate their activity and reduce excessive activation. Through these initiatives, Allakos aims to address significant unmet medical needs in immunological health.

VentureMed Group (VMG) designs, develops and markets innovative medical devices which enable interventionalists to cost effectively treat peripheral artery diseases and improve the lives of their patients. Founded by physicians who understand the clinical, medical and financial demands in today’s healthcare environment, VMG creates truly cost effective solutions. Their flagship product, the FLEX Scoring Catheter enables providers to reduce expensive inventory costs while offering the interventionalist more treatment options from a single device.

Neuros Medical, Inc. is a neuromodulation company based in Willoughby Hills, Ohio, that specializes in developing proprietary neurostimulation therapies to address unmet medical needs for patients globally. The company’s flagship technology, Electrical Nerve Block, targets the elimination of chronic pain associated with various conditions, including neuroma, residual limb pain, chronic post-surgical pain, and chronic migraines. Additionally, Neuros Medical offers the Neuros Altius System, which features an implantable generator with an integrated rechargeable battery, a cuff electrode, and external devices designed to enhance treatment outcomes. Founded in 2008, the company aims to provide innovative solutions for chronic pain management.

Amplyx Pharmaceuticals is a pre-clinical stage company focusing on the development of small molecule drugs with enhanced efficacy and lower toxicity. Amplyx employs a platform approach to improve small molecule drugs by the addition of a second small molecule to an existing drug. The company develops innovative therapies for debilitating and life-threatening diseases that affect people with compromised immune systems. Amplyx Pharmaceuticals was founded in 2006 and is headquartered in San Diego, California.

Genoa Pharmaceuticals, Inc., a biopharmaceutical company, develops therapies for the treatment of idiopathic pulmonary fibrosis (IPF). It develops GP-101, an aerosol pirfenidone formulation for direct inhalation delivery to the lungs for the treatment of IPF. The company was founded in 2011 and is based in San Diego, California.

Adarza BioSystems is an early-stage medical diagnostics company developing a rapid and label-free biological assay platform for measuring clinical and point-of-care (POC) samples. In addition to performing sophisticated clinical tests within minutes, this technology potentially allowing hundreds of tests to be run simultaneously on a single chip. It was founded in 2008 and headquartered in St Louis, Missouri.

Avalyn Pharma is a biopharma company that advances therapies for the treatment of Idiopathic Pulmonary Fibrosis (IPF) and other severe respiratory diseases. Its therapies rapidly advance AP01 for the treatment of IPF, provides additional pipeline candidates for IPF, improve the care and outcomes of severe respiratory diseases, and develop novel inhaled therapeutics. Avalyn Pharma was established in 2011 and is headquartered in Seattle, Washington.

Securus Medical Group engages in the development of clinical tools to improve the safety and efficacy of ablation therapy by providing real-time, non-contact, high-resolution tissue temperature monitoring, and mapping products. The company engages in developing real-time, noncontact, thermal mapping systems to determine intrabody tissue temperatures.

Tioma Therapeutics, Inc. operates as an immuno-oncology company that develops anti-CD47 antibodies for the treatment of solid and hematologic cancers. Tioma Therapeutics, Inc. was formerly known as Vasculox, Inc. and changed its name to Tioma Therapeutics, Inc. in August 2016. The company was founded in 2006 and is based in St. Louis, Missouri with a corporate office in Brisbane, California.

Spruce Biosciences is a clinical-stage biopharmaceutical focused on developing new treatments for rare endocrine disorders. The company is driven by its mission is to develop meaningful therapies for patients with rare diseases affecting the hypothalamic-pituitary-adrenal. They are committed to transforming the quality of life for patients who have been underserved by scientific innovation.

Amplyx Pharmaceuticals is a pre-clinical stage company focusing on the development of small molecule drugs with enhanced efficacy and lower toxicity. Amplyx employs a platform approach to improve small molecule drugs by the addition of a second small molecule to an existing drug. The company develops innovative therapies for debilitating and life-threatening diseases that affect people with compromised immune systems. Amplyx Pharmaceuticals was founded in 2006 and is headquartered in San Diego, California.

Lyric Pharmaceuticals Inc., a clinical-stage pharmaceutical company, develops therapeutics to improve the care of critically ill and hospitalized patients. The company develops ulimorelin, a macrocyclic agonist of the hormone ghrelin, as LP101 for the treatment of enteral feeding intolerance and for other disorders affecting critically ill patients in the ICU. It develops therapeutics for gastrointestinal indications. The company was founded in 2013 and is headquartered in South San Francisco, California.

Smart Wires is an electrical and electronics company that specializes in grid optimization solutions that leverage its patented modular power flow control technology. The company provides solutions in the fields of transmission reliability, congestion management, and power flow control solutions. Smart Wires was founded in 2010 and headquartered in San Francisco, California.

Allakos Inc. is a clinical-stage biopharmaceutical company based in Redwood City, California, founded in 2012. The company specializes in developing antibody-based therapeutics aimed at treating various diseases linked to dysregulation of the T-helper type 2 immune response, including allergic diseases, inflammation, and conditions characterized by excessive inflammatory cell production. Its lead therapeutic candidate, antolimab (AK002), targets conditions such as eosinophilic gastritis, eosinophilic gastroenteritis, chronic urticaria, indolent systemic mastocytosis, and severe allergic conjunctivitis. Additionally, Allakos is advancing another program, AK006, which targets the Siglec-6 receptor on mast cells to modulate their activity and reduce excessive activation. Through these initiatives, Allakos aims to address significant unmet medical needs in immunological health.

Tryton Medical, Inc. is a medical device company based in Durham, North Carolina, specializing in the development and manufacturing of side branch stent systems designed to treat coronary bifurcation lesions in patients with cardiovascular diseases. Founded in 2003, the company provides its innovative Tryton Side Branch Stent System, which targets atherosclerotic lesions at bifurcation sites. Tryton Medical distributes its products through a global network of distributors and also addresses investigational needs within the United States. The company's offerings are available in several countries, including Austria, Belgium, Denmark, Ireland, Luxembourg, the Netherlands, Norway, Poland, Portugal, Spain, and the United Kingdom.

Allakos Inc. is a clinical-stage biopharmaceutical company based in Redwood City, California, founded in 2012. The company specializes in developing antibody-based therapeutics aimed at treating various diseases linked to dysregulation of the T-helper type 2 immune response, including allergic diseases, inflammation, and conditions characterized by excessive inflammatory cell production. Its lead therapeutic candidate, antolimab (AK002), targets conditions such as eosinophilic gastritis, eosinophilic gastroenteritis, chronic urticaria, indolent systemic mastocytosis, and severe allergic conjunctivitis. Additionally, Allakos is advancing another program, AK006, which targets the Siglec-6 receptor on mast cells to modulate their activity and reduce excessive activation. Through these initiatives, Allakos aims to address significant unmet medical needs in immunological health.

Otonomy, Inc. is a biopharmaceutical company based in San Diego, California, focused on developing therapeutics for ear-related diseases and disorders. The company offers OTIPRIO, a ciprofloxacin otic suspension used during tympanostomy tube placement surgery in pediatric patients. Otonomy is advancing several product candidates, including OTIVIDEX, a sustained-release formulation of dexamethasone currently in Phase III trials for Ménière's disease, and OTO-313, which targets tinnitus and is in Phase I/II trials. Additionally, OTO-413 aims to treat cochlear synaptopathy and related hearing difficulties, while OTO-510 seeks to prevent hearing loss from cisplatin treatment. Another candidate, OTO-6XX, focuses on hair cell regeneration for severe hearing loss. Founded in 2008, Otonomy collaborates with various institutions and companies to enhance its research and development efforts in localized drug delivery for otologic disorders.

Lumena Pharmaceuticals focuses on developing oral therapeutics for rare liver diseases, aiming to enhance liver function and alleviate disease symptoms. The company's clinical-stage product candidates are designed to selectively target a transporter in the intestine, minimizing systemic absorption and reducing the risk of toxicities. Lumena's lead candidate, LUM001, has been thoroughly evaluated in over 12 clinical studies involving more than 1,400 subjects, positioning it for rapid advancement in clinical trials for both pediatric and adult patients with various forms of cholestatic liver disease. In addition to its primary objective of creating novel treatments for rare liver conditions, Lumena's innovative therapeutic approach also holds potential for addressing metabolic diseases affecting the liver, which represent a significant and growing health concern among both children and adults.

ZS Pharma, Inc. is a biopharmaceutical company based in Coppell, Texas, focused on developing non-absorbed drugs for renal, cardiovascular, liver, and metabolic diseases. Established in 2008, the company specializes in highly selective ion-trap therapies, particularly its lead candidate, ZS-9. This innovative treatment employs proprietary zirconium silicate technology to create ion traps that can effectively reduce excess potassium levels in patients suffering from hyperkalemia, a serious condition often associated with chronic kidney disease, hypertension, diabetes, and heart failure. ZS-9 is currently undergoing late-stage clinical trials to evaluate its efficacy and safety. As of December 2015, ZS Pharma operates as a subsidiary of Zeneca, Inc.

Securus Medical Group engages in the development of clinical tools to improve the safety and efficacy of ablation therapy by providing real-time, non-contact, high-resolution tissue temperature monitoring, and mapping products. The company engages in developing real-time, noncontact, thermal mapping systems to determine intrabody tissue temperatures.

Otonomy, Inc. is a biopharmaceutical company based in San Diego, California, focused on developing therapeutics for ear-related diseases and disorders. The company offers OTIPRIO, a ciprofloxacin otic suspension used during tympanostomy tube placement surgery in pediatric patients. Otonomy is advancing several product candidates, including OTIVIDEX, a sustained-release formulation of dexamethasone currently in Phase III trials for Ménière's disease, and OTO-313, which targets tinnitus and is in Phase I/II trials. Additionally, OTO-413 aims to treat cochlear synaptopathy and related hearing difficulties, while OTO-510 seeks to prevent hearing loss from cisplatin treatment. Another candidate, OTO-6XX, focuses on hair cell regeneration for severe hearing loss. Founded in 2008, Otonomy collaborates with various institutions and companies to enhance its research and development efforts in localized drug delivery for otologic disorders.

Lumena Pharmaceuticals focuses on developing oral therapeutics for rare liver diseases, aiming to enhance liver function and alleviate disease symptoms. The company's clinical-stage product candidates are designed to selectively target a transporter in the intestine, minimizing systemic absorption and reducing the risk of toxicities. Lumena's lead candidate, LUM001, has been thoroughly evaluated in over 12 clinical studies involving more than 1,400 subjects, positioning it for rapid advancement in clinical trials for both pediatric and adult patients with various forms of cholestatic liver disease. In addition to its primary objective of creating novel treatments for rare liver conditions, Lumena's innovative therapeutic approach also holds potential for addressing metabolic diseases affecting the liver, which represent a significant and growing health concern among both children and adults.

Tryton Medical, Inc. is a medical device company based in Durham, North Carolina, specializing in the development and manufacturing of side branch stent systems designed to treat coronary bifurcation lesions in patients with cardiovascular diseases. Founded in 2003, the company provides its innovative Tryton Side Branch Stent System, which targets atherosclerotic lesions at bifurcation sites. Tryton Medical distributes its products through a global network of distributors and also addresses investigational needs within the United States. The company's offerings are available in several countries, including Austria, Belgium, Denmark, Ireland, Luxembourg, the Netherlands, Norway, Poland, Portugal, Spain, and the United Kingdom.

Smart Wires is an electrical and electronics company that specializes in grid optimization solutions that leverage its patented modular power flow control technology. The company provides solutions in the fields of transmission reliability, congestion management, and power flow control solutions. Smart Wires was founded in 2010 and headquartered in San Francisco, California.

ZS Pharma, Inc. is a biopharmaceutical company based in Coppell, Texas, focused on developing non-absorbed drugs for renal, cardiovascular, liver, and metabolic diseases. Established in 2008, the company specializes in highly selective ion-trap therapies, particularly its lead candidate, ZS-9. This innovative treatment employs proprietary zirconium silicate technology to create ion traps that can effectively reduce excess potassium levels in patients suffering from hyperkalemia, a serious condition often associated with chronic kidney disease, hypertension, diabetes, and heart failure. ZS-9 is currently undergoing late-stage clinical trials to evaluate its efficacy and safety. As of December 2015, ZS Pharma operates as a subsidiary of Zeneca, Inc.

Neuros Medical, Inc. is a neuromodulation company based in Willoughby Hills, Ohio, that specializes in developing proprietary neurostimulation therapies to address unmet medical needs for patients globally. The company’s flagship technology, Electrical Nerve Block, targets the elimination of chronic pain associated with various conditions, including neuroma, residual limb pain, chronic post-surgical pain, and chronic migraines. Additionally, Neuros Medical offers the Neuros Altius System, which features an implantable generator with an integrated rechargeable battery, a cuff electrode, and external devices designed to enhance treatment outcomes. Founded in 2008, the company aims to provide innovative solutions for chronic pain management.

Securus Medical Group engages in the development of clinical tools to improve the safety and efficacy of ablation therapy by providing real-time, non-contact, high-resolution tissue temperature monitoring, and mapping products. The company engages in developing real-time, noncontact, thermal mapping systems to determine intrabody tissue temperatures.

IDEV Technologies is an emerging growth medical device company focused on the development of products for endovascular and interventional applications. Currently, IDEV markets SUPERA, a novel self-expanding nitinol stent. Using a patented interwoven design, SUPERA offers improved flexibility, radial strength, and kink and crush resistance compared to other marketed stents. SUPERA is currently approved for use in the treatment of biliary strictures in the US. IDEV is currently enrolling patients in the SUPERB IDE trial to study SUPERA's safety and efficacy when used in the superficial femoral artery (SFA).

Tryton Medical, Inc. is a medical device company based in Durham, North Carolina, specializing in the development and manufacturing of side branch stent systems designed to treat coronary bifurcation lesions in patients with cardiovascular diseases. Founded in 2003, the company provides its innovative Tryton Side Branch Stent System, which targets atherosclerotic lesions at bifurcation sites. Tryton Medical distributes its products through a global network of distributors and also addresses investigational needs within the United States. The company's offerings are available in several countries, including Austria, Belgium, Denmark, Ireland, Luxembourg, the Netherlands, Norway, Poland, Portugal, Spain, and the United Kingdom.

Accumetrics is a privately-held company based in San Diego, California, specializing in the development, manufacturing, and marketing of the VerifyNow System. This system comprises a comprehensive suite of assays designed for the assessment of platelet function, which is crucial in various medical applications, particularly in cardiovascular care. Founded in 1996, Accumetrics was initially sold to Radiometer in 2000 but was repurchased by its management and investors in 2003. The company continues to focus on providing essential tools for healthcare professionals to improve patient outcomes through effective monitoring of platelet activity.

Otonomy, Inc. is a biopharmaceutical company based in San Diego, California, focused on developing therapeutics for ear-related diseases and disorders. The company offers OTIPRIO, a ciprofloxacin otic suspension used during tympanostomy tube placement surgery in pediatric patients. Otonomy is advancing several product candidates, including OTIVIDEX, a sustained-release formulation of dexamethasone currently in Phase III trials for Ménière's disease, and OTO-313, which targets tinnitus and is in Phase I/II trials. Additionally, OTO-413 aims to treat cochlear synaptopathy and related hearing difficulties, while OTO-510 seeks to prevent hearing loss from cisplatin treatment. Another candidate, OTO-6XX, focuses on hair cell regeneration for severe hearing loss. Founded in 2008, Otonomy collaborates with various institutions and companies to enhance its research and development efforts in localized drug delivery for otologic disorders.

Established in 1999, Salient Surgical Technologies, Inc. is a global, privately held medical technology company that develops and markets advanced energy devices used in surgical procedures. Salient’s first line of products were monopolar electrosurgical devices used for the treatment of liver cancers. Today, the company’s bipolar AQUAMANTYS® System is used across a wide range of surgical procedures including orthopaedic reconstruction, spine surgery, orthopaedic trauma, and surgical oncology. Comprised of a bipolar electrosurgical generator & pump system and a portfolio of handheld disposable device, the AQUAMANTYS system uses patented TRANSCOLLATION® technology to haemostatically seal soft tissue and bone, enabling surgeons to reduce and prevent surgical blood loss. Salient’s products are sold throughout the United States, Europe, and Asia, providing clinical and economic benefits to hospitals, healthcare providers, and patients all over the world. To date, more than 500,000 patients have been treated with TRANSCOLLATION technology.

Accumetrics is a privately-held company based in San Diego, California, specializing in the development, manufacturing, and marketing of the VerifyNow System. This system comprises a comprehensive suite of assays designed for the assessment of platelet function, which is crucial in various medical applications, particularly in cardiovascular care. Founded in 1996, Accumetrics was initially sold to Radiometer in 2000 but was repurchased by its management and investors in 2003. The company continues to focus on providing essential tools for healthcare professionals to improve patient outcomes through effective monitoring of platelet activity.

Lutonix DCB is a new drug-coated balloon catheter that delivers paclitaxel to the arterial wall in a single, short inflation. Paclitaxel is an anti-proliferative drug commonly used to prevent arterial restenosis. Lutonix DCB is very similar to a standard angioplasty balloon, but contains a special coating consisting of paclitaxel and a proprietary carrier that facilitates the drug’s transfer to the arterial wall upon inflation. This highly efficient formulation allows Lutonix DCB to deliver a therapeutic dose to the artery wall, while keeping the dose of paclitaxel on the balloon as low as possible. A lower balloon drug load minimizes systemic drug exposure and is designed to maximize safety.

Accumetrics is a privately-held company based in San Diego, California, specializing in the development, manufacturing, and marketing of the VerifyNow System. This system comprises a comprehensive suite of assays designed for the assessment of platelet function, which is crucial in various medical applications, particularly in cardiovascular care. Founded in 1996, Accumetrics was initially sold to Radiometer in 2000 but was repurchased by its management and investors in 2003. The company continues to focus on providing essential tools for healthcare professionals to improve patient outcomes through effective monitoring of platelet activity.

Excaliard is a newly formed, venture capital-funded biotechnology company focused on the development and commercialization of antisense drugs for the local treatment of scarring and other fibrotic diseases.

Xoft, Inc. develops electronic brachytherapy (eBx) systems for radiation oncology applications. It offers Axxent Controller that utilizes a miniaturized high dose rate (HDR) X-ray source to apply radiation directly to the cancerous tumor bed. The company also provides Axxent balloon applicator, a treatment solution for accelerated partial breast irradiation; Axxent vaginal applicator that enables radiation oncologists to perform vaginal brachytherapy; and Axxent surface applicator that enables radiation oncologists to treat surface lesions. In addition, it offers accessories, such as physics accessory kits, personnel protective shields, procedure accessory packs, patient care kits, applicator clamp and base plates, and vacuum pumps, as well as FlexiShield, which drapes over the patient treatment area to reduce radiation transmission to nearby healthy tissue and organs. The company's products are used to treat early stage breast cancer, skin cancer, and endometrial cancer. It offers its products through physicians and distributors in Europe. Xoft, Inc. was formerly known as Xoft microTube, Inc. and changed its name in September 2004. The company was founded in 1998 and is based in Sunnyvale, California.

Calypso Medical Technologies, based in Seattle, is a privately held medical device company specializing in tumor localization technology. The company's proprietary system employs miniaturized implanted devices known as Beacon electromagnetic transponders to continuously and accurately track the location of tumors, enhancing the precision and management of radiation therapy delivery. This technology is particularly aimed at body-wide cancers that are commonly treated with radiation. Calypso's products have received FDA 510(k) clearance for use in the prostate and post-operative prostatic bed, ensuring compliance with regulatory standards. The company has established strategic partnerships with leading organizations in the medical field, including Varian Medical Systems, Siemens Medical Systems, Elekta Corporation, and Philips Medical, to further its mission of improving cancer treatment outcomes.

Cabrellis Pharmaceuticals Corporation, a specialty pharmaceutical company developing therapies for the treatment of cancer. Cabrellis plans to initiate three separate clinical trials in small cell lung cancer (SCLC) in 2006. The first trial, designed to assess the safety and efficacy of Calsed(TM) in reference to topotecan in the second-line treatment of patients with SCLC who previously responded to platinum-based chemotherapy, is currently underway at multiple clinical trial sites in the United States.

MacroGenics, Inc. is a biopharmaceutical company based in Rockville, Maryland, that specializes in the discovery and development of antibody-based therapeutics for cancer treatment. The company's pipeline includes several immuno-oncology candidates, such as Margetuximab, a monoclonal antibody currently in Phase III trials targeting HER2-expressing tumors, and Flotetuzumab, a DART molecule aimed at treating acute myeloid leukemia. Other investigational products include various monoclonal antibodies targeting immune checkpoints like PD-1 and B7-H3, as well as combination therapies that leverage multiple targets. MacroGenics employs advanced Fc engineering technology to enhance antibody functionality and is also exploring applications for autoimmune disorders and infectious diseases. The company has established strategic collaborations with several partners to advance its research and development efforts. Founded in 2000, MacroGenics is committed to innovating immunotherapeutics to address significant medical needs.

Kereos, Inc. is a biopharmaceutical company based in Saint Louis, Missouri, specializing in the development of targeted molecular imaging agents and therapeutics aimed at detecting and treating cancer and cardiovascular diseases. Established in 1999, Kereos utilizes a nanoscale drug delivery technology that enhances the targeting and efficacy of various therapeutic compounds, including existing drugs, new candidates, and those that may be too toxic or fragile for conventional delivery methods. The company's product portfolio includes KER-1001, a cancer therapeutic that combines paclitaxel with a targeted nanodroplet, KER-1002, which integrates a natural anti-tumor agent, and KER-1003, known for its anti-angiogenic properties. Additionally, Kereos offers diagnostic solutions such as KER 0001, designed to detect angiogenesis. The company also collaborates with pharmaceutical and imaging firms to further develop its MRI agents and targeted chemotherapeutics for solid tumors and cardiovascular applications.

Centerre Healthcare Corporation, founded in 2002 and based in Brentwood, Tennessee, operates rehabilitation hospitals that focus on comprehensive care for patients recovering from various conditions. The organization offers specialized inpatient rehabilitation services for individuals dealing with strokes, brain injuries, spinal cord injuries, burns, traumatic injuries, and orthopedic issues such as hip and knee replacements. Centerre Healthcare is dedicated to addressing the medical, psychological, social, and functional needs of its patients, aiming to support their independence and enhance their quality of life following injury or illness.

Velocimed was founded by a group of well known medical entrepreneurs. The company's founders envisioned a company that would become a global leader in the identification and development of innovative technologies with the power to improve the lives of patients whose clinical needs are not being met. Lead by a seasoned management team, Velocimed creates products internally and also looks externally for new technologies by partnering with physicians, inventors and institutions -- particularly those who may lack access to the necessary resources required for early development of new ideas. At Velocimed, they believe that they own a unique position in medical innovation and commercialization. Unlike small incubators, they have the expertise to commercialize viable technology. And unlike large companies, they have the ability to pinpoint opportunities faster and move more quickly.

Auxeris Therapeutics is a biopharmaceutical company focused on the development and commercialization of medicines to treat a broad range of bone diseases. The company develops drugs to treat fracture repair, spinal fusion, and bone diseases, including osteoporosis. Auxeris Therapeutics was founded in 2002 and is based in St. Louis, Missouri.

Established in 1999, Salient Surgical Technologies, Inc. is a global, privately held medical technology company that develops and markets advanced energy devices used in surgical procedures. Salient’s first line of products were monopolar electrosurgical devices used for the treatment of liver cancers. Today, the company’s bipolar AQUAMANTYS® System is used across a wide range of surgical procedures including orthopaedic reconstruction, spine surgery, orthopaedic trauma, and surgical oncology. Comprised of a bipolar electrosurgical generator & pump system and a portfolio of handheld disposable device, the AQUAMANTYS system uses patented TRANSCOLLATION® technology to haemostatically seal soft tissue and bone, enabling surgeons to reduce and prevent surgical blood loss. Salient’s products are sold throughout the United States, Europe, and Asia, providing clinical and economic benefits to hospitals, healthcare providers, and patients all over the world. To date, more than 500,000 patients have been treated with TRANSCOLLATION technology.

Conforma Therapeutics Corporation designs and develops drugs for the treatment of cancer. It develops drugs that induce tumor cells to degrade the proteins that promote cancer growth. The company offers HSP90 and CNF1010 which are used for the treatment of cancer. The company was incorporated in 1999 and is based in San Diego, California

Velocimed was founded by a group of well known medical entrepreneurs. The company's founders envisioned a company that would become a global leader in the identification and development of innovative technologies with the power to improve the lives of patients whose clinical needs are not being met. Lead by a seasoned management team, Velocimed creates products internally and also looks externally for new technologies by partnering with physicians, inventors and institutions -- particularly those who may lack access to the necessary resources required for early development of new ideas. At Velocimed, they believe that they own a unique position in medical innovation and commercialization. Unlike small incubators, they have the expertise to commercialize viable technology. And unlike large companies, they have the ability to pinpoint opportunities faster and move more quickly.

NexRay is a provider of medical x-ray fluoroscopy systems.

Established in 1999, Salient Surgical Technologies, Inc. is a global, privately held medical technology company that develops and markets advanced energy devices used in surgical procedures. Salient’s first line of products were monopolar electrosurgical devices used for the treatment of liver cancers. Today, the company’s bipolar AQUAMANTYS® System is used across a wide range of surgical procedures including orthopaedic reconstruction, spine surgery, orthopaedic trauma, and surgical oncology. Comprised of a bipolar electrosurgical generator & pump system and a portfolio of handheld disposable device, the AQUAMANTYS system uses patented TRANSCOLLATION® technology to haemostatically seal soft tissue and bone, enabling surgeons to reduce and prevent surgical blood loss. Salient’s products are sold throughout the United States, Europe, and Asia, providing clinical and economic benefits to hospitals, healthcare providers, and patients all over the world. To date, more than 500,000 patients have been treated with TRANSCOLLATION technology.